ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed on the ASCIA website www.allergy.org.au/ascia-submissions

ASCIA lodged five submissions on 23 January 2025 in support for the following applications which are relevant to clinical immunology/allergy specialists, to be considered at the March 2025 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC):

• Extension of PBS listing of Dupixent^® (dupilumab) for patients aged less than 12 years 
  ASCIA letter PBAC Dupixent 2025-01-23 121.54 KB

• PBS listing of a new strength of Xolair^® (omalizumab)
  ASCIA letter PBAC Xolair 2025-01-23119.62 KB

• New PBS listing of Omlyclo^® (omalizumab)
  ASCIA letter PBAC Omlyclo 2025-01-23117.80 KB

• Amendment to PBS listing of Remsima^® SC (infliximab)
  ASCIA letter PBAC Remsima SC 2025-01-23 119.47 KB

• New PBS listing of Ixifi^® (infliximab)  
  ASCIA letter PBAC Ixifi 2025-01-23 117.85 KB

This news item was issued on 5 February 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.